Background The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

INTRODUCTION Immunotherapy targeting the programmed cell death protein–1 (PD-1) axis
elicits durable antitumor responses in multiple cancer types. However, clinical responses …

Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part 1 of …

Background Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an
urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 …

Purpose: Tumor-associated PD-L1 expression is predictive of clinical response to PD-1–directed
immunotherapy. However, PD-L1–negative patients may also respond to PD-1 …

The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is essential for the
replication of viral RNA and thus constitutes a valid target for the chemotherapeutic …

The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection
requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We …

Improved treatments for chronic hepatitis C virus (HCV) infection are needed due to the
suboptimal response rates and deleterious side effects associated with current treatment options. …

Chikungunya virus (CHIKV) infection causes acute disease characterized by fever, rash and
arthralgia, which progresses to severe and chronic arthritis in up to 50% of patients. …